How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

848 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Full Text available with Trip Pro

Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease. Rivastigmine transdermal patches for the treatment of Alzheimer's disease (AD) have potential benefits compared to capsules because of their sustained absorption through the skin, good local tolerability and reduction of gastrointestinal problems.To assess gastrointestinal and skin tolerability and the need for optimal dose titration of rivastigmine transdermal patches (...) in Alzheimer's disease patients previously treated with oral rivastigmine.A multicenter, randomized, open-label study including patients with mild to moderate AD (DSM-IV) previously treated with rivastigmine capsules (6-12 mg/day) was conducted. Patients were randomized to: continue with capsules for 3 months (n=49) or switch to rivastigmine patch without titration (9.5mg/day for 3 months; n=48), or switch to rivastigmine patch with titration (4.6 mg/day for 1 month followed by 9.5mg/day for 2 months, n=43

2011 Neurología (Barcelona, Spain) Controlled trial quality: uncertain

122. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. (Abstract)

Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. The rationale for the development of the rivastigmine transdermal patch was to improve upon an efficacious therapy by mitigating certain adverse events, such as nausea and vomiting. This may be particularly important in Alzheimer disease patients with low body weights, who may be more susceptible to these adverse events. This analysis compared (...) the effect of body weight on tolerability in Alzheimer disease patients receiving rivastigmine capsules or rivastigmine patch. Using data from a 24-week trial, adverse events and discontinuations were evaluated in patients stratified on the basis of extreme low weight (<50 kg), medium weight (50 to 80 kg), and high weight (>80 kg) at baseline. Rivastigmine patch was generally well tolerated, regardless of patient body weight. Among patients receiving rivastigmine patch, lower body weight, as stratified

2011 Alzheimer disease and associated disorders Controlled trial quality: uncertain

123. Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Full Text available with Trip Pro

Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Compared to smokers alone, smokers with co-morbid substance use disorders are at greater risk of suffering from smoking-related death. Despite this, relatively few studies have examined smoking cessation treatments for those with stimulant dependence. In the current study, we sought to evaluate the effects produced by short-term exposure to the cholinesterase inhibitor rivastigmine (0, 3 or 6 (...) mg) on cigarette smoking in non-treatment-seeking, methamphetamine-dependent volunteers. This was a double-blind, placebo-controlled, crossover study that took place over 9 days. The data indicate that rivastigmine treatment did not alter Fagerström Test for Nicotine Dependence scores, carbon monoxide readings, or cigarettes smoked per day, but a trend toward reduced urges to smoke (p<0.09) was detected during treatment with rivastigmine 3mg. These data, while preliminary, indicate

2011 Progress in neuro-psychopharmacology & biological psychiatry Controlled trial quality: uncertain

124. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. (Abstract)

The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue. Cognitive decline and fatigue are typical in multiple sclerosis (MS). However, there is no official medication for either of these symptoms.The purpose of this study was to estimate the effects of a single dose of rivastigmine on processing speed and associated brain activity in patients with MS and subjective cognitive fatigue.Fifteen patients with MS (...) and subjective cognitive fatigue and 13 healthy controls (HCs) matched for age, gender and education performed a neuropsychological assessment and functional (f)MRI. A modified version of the Paced Visual Serial Addition Test (mPVSAT) was used as the behavioural task during fMRIs. After the first scanning session, both groups were randomly divided into two subgroups receiving either rivastigmine or placebo. A single dose of rivastigmine or placebo was administrated double-blindly and 2.5 hours later

2011 Multiple sclerosis (Houndmills, Basingstoke, England) Controlled trial quality: uncertain

125. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. Full Text available with Trip Pro

A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer's disease. As of 2010, the rivastigmine patch was licensed for the treatment of Alzheimer's disease (AD) in 64 countries.This 24-week, multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy, safety and tolerability of the 5-cm(2) (9-mg loading dose; 4.6 mg/24 h delivery rate) and 10-cm(2) (18 (...) -mg loading dose; 9.5 mg/24 h delivery rate) rivastigmine patch in Japanese patients with AD.In the primary analysis population (intent-to-treat last observation carried forward) at week 24, delayed deterioration was seen with the 10-cm(2) patch versus placebo on the Japanese version of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-J cog; p = 0.005) and the Japanese version of the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC plus-J; p = 0.067

2011 Dementia and geriatric cognitive disorders extra Controlled trial quality: predicted high

126. Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine

Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine (CAREER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01380288 Recruitment Status : Completed First Posted

2011 Clinical Trials

127. An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke. (Abstract)

An open-label pilot study of the use of rivastigmine to promote functional recovery in patients with unilateral spatial neglect due to first ischemic stroke. The aim of this study was to evaluate the efficacy and safety of rivastigmine as add-on treatment to specific cognitive rehabilitation for unilateral spatial neglect (USN). Twenty patients were randomly assigned either to rehabilitation treatment only (No-RIV) or to rivastigmine (3 mg twice a day, for 8 weeks) add-on treatment (RIV+,). USN (...) . Rivastigmine as add-on treatment to specific cognitive training for USN may improve and accelerate recovery on some specific impairment tests as compared with cognitive training alone.

2011 Functional neurology Controlled trial quality: uncertain

128. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. (Abstract)

Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease. The cholinesterase inhibitor rivastigmine is available in both oral and transdermal forms. The efficacy of oral rivastigmine appears to be dose-dependent. The current analysis investigates the effect of dose on the efficacy of the rivastigmine transdermal patch.This was a retrospective analysis of a large, international, 24-week, randomised, placebo- and active-controlled trial (...) (IDEAL, CENA713D2320) of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD). Patients received the 9.5 mg/24 h rivastigmine patch, the 17.4 mg/24 h rivastigmine patch, 12 mg/day rivastigmine capsules or placebo. Changes from baseline at week 24 on the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale were calculated based on the patient's

2011 International journal of clinical practice Controlled trial quality: uncertain

129. Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. Full Text available with Trip Pro

Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses. In Alzheimer's disease (AD), rivastigmine has demonstrated statistically significant efficacy versus placebo on cognition and activities of daily living (ADL). The aim of this retrospective analysis was to further evaluate the treatment effects of rivastigmine on individual ADL items.This exploratory analysis focused on the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL (...) ) outcome from a large, international, 24-week, controlled trial of rivastigmine once-daily transdermal patch and twice-daily capsules in AD (CENA713D2320, NCT00099242). Percentages of patients "improving" or "not worsening" on individual ADL items were calculated and changes from baseline with rivastigmine versus placebo were evaluated.Patients received rivastigmine patch (9.5 mg/24 h; n = 247), capsule (12 mg/day; n = 254), and placebo (n = 281). Statistically significant changes from baseline

2011 International Journal of Geriatric Psychiatry Controlled trial quality: uncertain

130. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. (Abstract)

Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study. To compare the tolerability and efficacy of combination therapy of memantine plus rivastigmine patch with rivastigmine patch monotherapy in patients with mild to moderate Alzheimer's disease (AD).In this multicenter, randomized, open-label study, patients entered an 8-week run-in period (a 5 cm 2 (...) rivastigmine patch for 4 weeks, then a 10 cm(2) patch for 4 weeks) followed by 16 weeks of memantine plus rivastigmine patch or rivastigmine patch monotherapy. The primary outcome measure was the retention rate at the end of the trial.clinicaltrials.gov. NCT01025466.Overall, 88 and 84 patients received rivastigmine patch with and without memantine, respectively, and of these, 77 (87.5%) and 70 (83.3%) patients completed the study. The difference in retention rate was not significant (95% confidence

2011 Current medical research and opinion Controlled trial quality: predicted high

131. Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. (Abstract)

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease. Rivastigmine patches provide similar efficacy to rivastigmine capsules with a lower incidence of gastrointestinal side effects in patients with probable Alzheimer's disease (AD).Post hoc analysis of a 24-week, prospective, international, randomized, double-blind, placebo- and active-controlled trial. Patients (n = 892) with probable AD received rivastigmine transdermal patches (9.5 mg/24 hours [10 cm (...) (2)]), rivastigmine capsules (6 mg twice daily), or placebo, and impact on activities of daily living (ADLs) was assessed utilizing 3 subscales: basic, high-level function, and autonomy.At week 24, both rivastigmine groups demonstrated significantly superior performance in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Total Score versus placebo (rivastigmine patch, P = .013; capsules, P = .039). Overall, both rivastigmine formulations provided benefits in ADL

2011 American journal of Alzheimer's disease and other dementias Controlled trial quality: predicted high

132. Dementia: assessment, management and support for people living with dementia and their carers

dementia subtypes Managing medicines for all dementia subtypes 1.5.1 For guidance on managing medicines (including covert administration), see the NICE guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. Pharmacological management of Alzheimer's disease Pharmacological management of Alzheimer's disease 1.5.2 The three acetylcholinesterase (AChE) inhibitors donepezil, galantamine and rivastigmine as monotherapies are recommended (...) as options for managing mild to moderate Alzheimer's disease under all of the conditions specified in 1.5.5 and 1.5.6. This recommendation is from NICE technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 1.5.3 Memantine monotherapy is recommended as an option for managing Alzheimer's disease for people with: moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors or or Dementia: assessment

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

134. Pharmacological interventions for the treatment of delirium in critically ill adults. (Abstract)

; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and cholinesterase (CHE) inhibitors (n = 1; rivastigmine). Only one of these trials consistently used non-pharmacological interventions that are known to improve patient outcomes in both intervention and control groups.Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome. Results of the NMA showed that the intervention with the smallest ratio of means (RoM (...) antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high-quality evidence).The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate-quality evidence), and the CHE inhibitor rivastigmine was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate-quality evidence). Adverse events often were not reported in these trials or, when reported

2019 Cochrane

135. Parkinson?s disease in adults

for further information. [4] At the time of publication (July 2017), quetiapine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [5] At the time of publication (July 2017), rivastigmine capsules are the only treatment (...) with a UK marketing authorisation for this indication. Donepezil, galantamine and rivastigmine patches did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information. [6] At the time of publication (July 2017), cholinesterase inhibitors

2017 National Institute for Health and Clinical Excellence - Clinical Guidelines

136. Clinical practice guidelines for pain, agitation, delirium, sedation and mobilisation in the intensive care unit: A Rapid Review

. There is no published evidence that treatment with haloperidol reduces the duration of delirium in adult ICU patients. No evidence ii. Atypical antipsychotics may reduce the duration of delirium in adult ICU patients. Low iii. We do not recommend administering rivastigmine to reduce the duration of delirium in ICU patients. Moderate iv. We do not suggest using antipsychotics in patients at significant risk for torsades de pointes (i.e., patients with baseline prolongation of QTc interval, patients receiving

2019 Monash Health Evidence Reviews

139. Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia

Galantamine Versus Placebo and Galantamine Dose Comparisons 101 Key Messages 101 Eligible Studies 101 Baseline Study Characteristics 101 Outcomes 102 Variation in Outcomes by Participant Characteristics 103 Rivastigmine Versus Placebo 104 Key Messages 104 Eligible Studies 104 Baseline Study Characteristics 104 Outcomes 105 Variation in Outcomes by Participant Characteristics 108 Rivastigmine Dosage Comparisons 108 Key Messages 108 Eligible Studies 109 Baseline Study Characteristics 109 Outcomes 110 (...) 128 Eligible Studies 128 Gingko Biloba Versus Donepezil 128 Vitamin E Versus Donepezil 130 Huannao Yicong Formula Versus Donepezil 131 Vitamin E Versus Rivastigmine 132 Saffron Extract Versus Memantine 133 Additional Drug Versus Drug Comparisons 134 Key Message 134 Eligible Studies 134 Chapter 9. Key Question 6: Prescription Drugs Versus Placebo for Behavioral and Psychological Symptoms of Dementia 135 Antipsychotics Versus Placebo and Antipsychotic Dose Comparisons 135 Key Messages 135 Eligible

2020 Effective Health Care Program (AHRQ)

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>